Enter inventor name

Eckhard Guenther

USPTO Granted Patents = 16 (Patent Applications = 3)

Average Co-Inventor Count = 6.3

ph-index = 2

Forward Citations = 84(Granted Patents)

Company Filing History:

12 out of 36

Aeterna Zentaris Gmbh

Years Active: 2004-2015

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8937068 - Pyridopyrazine derivatives and their use (2015-01-20),

2. 8912189 - Pyridopyrazine derivatives and their use (2014-12-16),

3. 8791118 - Pyridopyrazines as highly selective ras-Raf-Mek-Erk signal transduction pathway inhibitors (2014-07-29),

4. 8604196 - Modulating signal transduction pathways with 1-ethyl-3-[3-(1-methyl-1H-pyrazol-4-yl)-pyrido[2.3-B]pyrazine-6-yl]thiourea (2013-12-10),

5. 8541462 - Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors (2013-09-24),

6. 8536332 - Modulating signal transduction pathways with substituted pyridol [2,3-b] pyrazines (2013-09-17),

7. 8507486 - Pyridopyrazine derivatives, process of manufacturing and uses thereof (2013-08-13),

8. 8470776 - Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof (2013-06-25),

9. 8461178 - Naphthyridine derivatives and the use thereof as kinase inhibitors (2013-06-11),

10. 8394801 - Quinoxaline derivatives and their use for treating benign and malignant tumour disorders (2013-03-12),

11. 8217042 - Pyridopyrazines and their use as modulators of kinases (2012-07-10),

12. 8202883 - Substituted pyrido[2,3-b]pyrazine compounds as modulators of tyrosine kinases (2012-06-19),

13. 8148546 - Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors (2012-04-03),

14. 7741277 - Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof (2010-06-22),

15. 7378522 - Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone (2008-05-27),

Title: The Innovative Mind of Eckhard Guenther: Pioneering Pyridopyrazine Compounds

Introduction

Eckhard Guenther, an accomplished inventor based in Maintal, Germany, is recognized for his significant contributions to the field of medicinal chemistry. With a remarkable portfolio of 16 patents, Guenther has dedicated his career to developing innovative compounds that address various physiological and pathophysiological conditions in mammals, particularly humans.

Latest Patents

One of Guenther's most notable inventions revolves around pyridopyrazine derivatives, which are compounds suitable for the treatment or prevention of physiological and/or pathophysiological states. His recent patents delve deep into the modulation of signal transduction pathways and enzymes, showcasing compounds of general formula (I) that hold promise in therapeutic applications. These advancements underscore the potential impact of pyridopyrazine compounds in modern medicine, paving the way for new treatment modalities.

Career Highlights

Throughout his career, Eckhard Guenther has been associated with prominent companies such as Aeterna Zentaris GmbH and Zentaris AG. His work in these organizations has significantly advanced the research and development of pharmaceutical solutions, particularly in the realm of signal transduction and enzyme modulation.

Collaborations

Guenther's innovative spirit has fostered collaboration with esteemed colleagues, including Tilmann Schuster and Emmanuel Polymeropoulos. Together, they have contributed to groundbreaking research and development initiatives, enhancing the potential of new pharmaceutical compounds.

Conclusion

Eckhard Guenther's contributions to the field of medicinal chemistry through his extensive patent portfolio underline his role as a leading inventor. His pioneering work with pyridopyrazine derivatives not only exemplifies innovative thinking but also highlights the importance of collaboration in driving medicinal advancements. As research continues, the impact of Guenther’s work is likely to resonate well beyond the realms of academia and industry, potentially improving countless lives through better therapeutic options.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com